Tren/Test 350
Tren/Test 350 Dragon Pharma — Overview
Tren/Test 350 Dragon Pharma is a pre-mixed injectable blend combining two of the most widely used long-ester anabolic-androgenic compounds in a single vial: Trenbolone Enanthate at 100 mg/ml and Testosterone Enanthate at 250 mg/ml, yielding 350 mg of total AAS per millilitre. The 2.5:1 Testosterone-to-Trenbolone ratio is deliberately positioned within the range most commonly recommended for managing trenbolone's androgenic and progestogenic side effects while maintaining a strong anabolic base — running testosterone at a meaningful multiple of the trenbolone dose prevents androgen deficiency symptoms and provides the estrogenic support that trenbolone itself cannot supply. Both compounds carry the Enanthate ester, meaning matched pharmacokinetics, a shared active life of approximately 7–10 days, and a twice-weekly injection schedule that covers both hormones in a single shot.
The practical advantage of a pre-mixed Tren/Test blend is protocol simplification at the advanced level: instead of managing two separate vials, two separate dosing schedules, and the injection volume arithmetic of combining two compounds, each injection delivers a fixed, calibrated ratio in one draw. At 1 ml twice weekly, the blend produces 200 mg Tren E and 500 mg Test E per week — a moderate-to-advanced starting point suitable for experienced users familiar with trenbolone's side effect profile. steroidwarehouse.com carries both the Tren/Test 350 blend and the individual compounds for users who require independent dose adjustment of each component.
About the Compound: Dual Mechanism in One Vial
Tren/Test 350 combines two structurally distinct anabolic compounds whose pharmacological profiles are complementary in ways that explain why the Testosterone + Trenbolone stack has become one of the most persistent protocols in advanced bodybuilding.
- Testosterone Enanthate 250 mg/ml — the anabolic and estrogenic base — testosterone is the primary endogenous androgen and the reference compound against which all synthetic AAS are benchmarked; testosterone enanthate binds the androgen receptor (AR) to drive muscle protein synthesis, nitrogen retention, red blood cell production, and IGF-1 secretion; it aromatises via the CYP19A1 enzyme to oestradiol (E2), which is responsible for both estrogenic side effects (water retention, gynecomastia risk) and the beneficial estrogenic effects that prevent joint pain, libido suppression, and mood deterioration during an AAS cycle; in the Tren/Test 350 blend, the Test E component serves a dual role: it provides the anabolic mass-building foundation AND the estrogenic activity that trenbolone's total AR selectivity deliberately avoids; at 500 mg/week (1 ml × 2 injections), Test E drives substantial anabolic stimulus while requiring active AI management to keep E2 in the optimal range of 20–40 pg/mL
- Trenbolone Enanthate 100 mg/ml — the 19-Nor powerhouse — trenbolone is a 19-Nor (19-nortestosterone derivative) synthetic androgen with an androgen receptor binding affinity approximately five times greater than testosterone; it does not aromatise to oestradiol, meaning trenbolone itself contributes zero E2 load; however, as a 19-Nor compound it exhibits significant progestogenic activity through progesterone receptor binding, which is the mechanism behind its prolactin-elevating effect and the progestogenic gynecomastia risk that requires cabergoline management distinct from AI management; trenbolone strongly suppresses LH and FSH (more profoundly than testosterone alone), significantly inhibits glucocorticoid receptors (anti-catabolic effect), increases nutrient partitioning efficiency, and produces the dense, dry, vascular muscle appearance associated with its use; at 200 mg/week (the blend dose at 1 ml × 2 injections), trenbolone provides strong AR stimulation with a manageable side effect threshold for experienced users; the enanthate ester gives trenbolone a half-life of approximately 7–10 days, matched to the Test E ester for fully synchronised pharmacokinetics and identical injection scheduling
- Why the 2.5:1 Test:Tren ratio is purposeful — running testosterone at a meaningful multiple of the trenbolone dose is the most reliable approach for managing trenbolone's androgenic dominance; trenbolone's extremely high AR affinity means it competes with testosterone for receptor occupancy; in the absence of adequate testosterone, androgenic deficiency symptoms (low libido, erectile dysfunction, mood deterioration) are common despite supraphysiologic total androgen load because trenbolone does not fully substitute for testosterone's broader physiological roles; the 2.5:1 ratio in this blend ensures testosterone provides sufficient hormonal coverage while trenbolone delivers its anabolic amplification; users who require different ratios — more trenbolone per cycle or more testosterone — will supplement the blend with additional standalone compound rather than altering the blend itself
- Enanthate ester pharmacokinetics — practical implications — the enanthate ester attached to both trenbolone and testosterone produces a release curve that peaks approximately 48–72 hours post-injection and declines over 7–10 days; twice-weekly injection (every 3–4 days) maintains stable plasma concentrations without the peaks and troughs of once-weekly dosing; stable plasma levels are important for E2 management (AI dosing becomes predictable) and for prolactin management (cabergoline schedule is reliable); the enanthate ester also means that cycle cessation requires 2 weeks of clearance time before PCT begins, as the ester-bound hormone depot continues releasing active compound after the last injection
What Tren/Test 350 Does
- Lean mass accrual with exceptional quality — the combination of testosterone's anabolic volume and trenbolone's superior AR affinity produces lean muscle gains with significantly less water retention and fat co-gain than testosterone-only protocols at equivalent androgenic load; trenbolone's glucocorticoid receptor antagonism blocks cortisol-mediated muscle protein breakdown, making the mass gained during a Tren/Test cycle harder and more retainable post-cycle than mass gained on aromatising-only AAS stacks; users typically report 8–15 lb of lean tissue gain over a 12-week cycle depending on training, nutrition, and dosing, with a substantially drier appearance than comparable testosterone-only or testosterone plus nandrolone cycles
- Dramatic strength increases — trenbolone's extremely high AR binding translates into rapid and substantial strength gains that exceed what testosterone alone produces per milligram of AR stimulation; the mechanism involves increased phosphocreatine resynthesis, IGF-1 upregulation, and direct AR signaling in muscle fibres; most users report noticeable strength increases within 2–3 weeks of starting a Tren E cycle, with compounding gains through weeks 6–10; strength gains on Tren/Test 350 tend to be more sustainable than those on short-ester trenbolone acetate because the plasma concentrations are more stable
- Superior nutrient partitioning — trenbolone is widely regarded as the most potent nutrient partitioner among commercially used AAS; it dramatically increases the proportion of dietary protein and calories directed toward muscle protein synthesis versus fat storage; this effect is so pronounced that body recomposition (simultaneous muscle gain and fat loss) is achievable on Tren/Test 350 even at moderate caloric surplus, and aggressive body recomp (significant fat loss during a caloric deficit while gaining or maintaining lean mass) is achievable even in deficit phases; this nutrient partitioning effect is the primary reason trenbolone is used in pre-contest bodybuilding protocols despite its harsh side effect profile
- Significant fat loss and body recomposition — trenbolone's glucocorticoid antagonism, increased metabolic rate (night sweats are a visible marker of elevated basal metabolic expenditure), and superior AR stimulation in adipose tissue combine to produce measurable fat mass reduction even during mass-gain phases; the testosterone component supports metabolic rate and IGF-1 levels that further support fat mobilisation; the combination delivers both the anabolic stimulus for muscle growth and the metabolic stimulus for fat utilisation simultaneously, which is the defining characteristic that makes Tren/Test a recomp compound rather than a pure bulk compound like testosterone plus nandrolone
- Vascular, dense, aesthetic muscle appearance — the minimal water retention from trenbolone (no aromatization from the tren component, with E2 managed from the test component) combined with increased red blood cell production and enhanced muscle glycogen storage produces the dense, hard, vascular appearance associated with trenbolone use; subcutaneous water is markedly reduced compared to aromatising-only stacks; vascularity increases substantially as plasma volume expands (from elevated EPO-like hematocrit effects) and subcutaneous water decreases; this is the visual combination that makes Tren/Test 350 a competitive bodybuilding compound rather than a bulking-only choice
Who It's For
- What sets Tren/Test 350 apart from other stacks: the pre-mixed Enanthate ester blend is the key differentiator from running the same compounds separately; matched esters means one injection, one frequency, and stable co-peak pharmacokinetics — removing injection management complexity from an already demanding protocol; compared to a Tren Acetate + Test Propionate combination (short-ester equivalent), the Enanthate blend requires significantly fewer injections, has a more stable plasma profile after the first 2 weeks of steady-state, and produces less injection discomfort from short-ester compounds; compared to Test + Deca (nandrolone) stacks, Tren/Test produces substantially more strength, superior lean mass quality, greater nutrient partitioning, and better body recomposition but with a significantly more demanding side effect management requirement; compared to Test-only cycles, the addition of trenbolone multiplies the anabolic output per week of cycle without proportionally multiplying estrogenic exposure, since trenbolone itself contributes no aromatization
- Best scenario: experienced AAS users with at least one prior trenbolone cycle (ideally acetate first, for side effect assessment) who want maximum lean mass and body composition change from a twice-weekly injectable protocol; competitive bodybuilders in off-season lean bulk or 12–20 week pre-contest preparation phases; users who have already optimised their AI, cabergoline, and cardiovascular support protocols from prior cycles and can manage trenbolone's specific side effect profile (night sweats, elevated BP, prolactin) systematically; users who value protocol simplicity and want the testosterone and trenbolone ratio fixed rather than variable
- Choose something else instead: any user who has not used trenbolone before — the first trenbolone experience should be with Trenbolone 100 Dragon Pharma (Trenbolone Acetate), which has a 2–3 day half-life allowing rapid dose reduction or discontinuation if side effects are intolerable; the short ester provides a safety buffer that the enanthate blend does not; users prone to severe androgenic side effects (significant hair loss acceleration, prostate sensitivity, aggressive mood changes) who have not confirmed trenbolone tolerance; users wanting a "dry and lean" look without the cardiovascular and sleep disruption demands of trenbolone — Masteron 200 Dragon Pharma combined with Enantat 250 Dragon Pharma delivers a dry, anti-estrogenic look with a substantially cleaner side effect profile
Tren/Test 350 vs Alternatives
| Compound | Key Differences | Choose Tren/Test 350 When | Choose Alternative When |
|---|---|---|---|
| Trenbolone 200 Dragon Pharma + Enantat 250 Dragon Pharma Tren E 200 mg/ml · Test E 250 mg/ml separately |
Same compounds, fully independent dosing; running separately allows adjustment of each component without affecting the other — e.g. increasing tren from 200 to 300 mg/week while keeping test at 500 mg, or adjusting the test:tren ratio mid-cycle based on bloodwork; requires two injections per session but gives complete dose flexibility; same ester, same frequency; cost per milligram may vary | The 2.5:1 Test:Tren ratio in the blend fits the target protocol exactly and separate vial management is unnecessary; protocol simplicity and single-draw convenience are priorities | Independent dose titration of each component is needed — e.g. higher tren relative to test for contest prep, or adjusting test dose based on E2 bloodwork without changing tren dose; or when one component needs to be stopped/reduced without altering the other |
| Trenbolone 100 Dragon Pharma + Enantat 250 Dragon Pharma Tren Acetate 100 mg/ml · Test E separately |
Trenbolone Acetate has a 2–3 day half-life versus 7–10 days for Enanthate; this requires EOD or daily injections for stable tren plasma levels (more injections) but provides faster dose adjustment and much quicker side effect clearance if tren is discontinued; mismatched esters with Test E means the tren component peaks and troughs faster than the test base; acetate is the preferred first-time tren ester because any intolerable side effect resolves within 3–5 days of stopping; enanthate side effects take 2–3 weeks to clear after the last injection | Confirmed trenbolone tolerance from prior acetate use exists; twice-weekly injection schedule is specifically required; the longer ester's stability and convenience outweigh the flexibility advantage of acetate | First trenbolone cycle — acetate's short half-life is a critical safety feature for side effect management; or when fine dose control and fast washout capability are priorities over injection convenience |
| Masteron 200 Dragon Pharma + Enantat 250 Dragon Pharma Drostanolone Enanthate 200 mg/ml · Test E 250 mg/ml |
Masteron (drostanolone enanthate) is a DHT-derivative with mild anabolic activity, strong anti-estrogenic properties (displaces E2 from SHBG, mild aromatase inhibitory activity in tissue), and a dry, hard muscle appearance; it does not suppress sleep, does not cause significant night sweats, has no prolactin elevation risk, and has no cardiovascular impact comparable to trenbolone's; gains are leaner and more moderate than trenbolone but with a far more manageable side effect profile; Masteron + Test E is frequently used as a pre-contest hardening stack for intermediate-level users who want a dry look without trenbolone's demands | Maximum anabolic output, nutrient partitioning, and strength are the primary goals and trenbolone's side effect profile is tolerable and manageable | The trenbolone side effect profile (night sweats, sleep disruption, cardiovascular strain, prolactin management, aggression) is not acceptable or tolerable for the user's current context; or the user is intermediate rather than advanced and a milder dry stack is appropriate |
Combinations
| Goal | Stack | Notes |
|---|---|---|
| Lean bulk / recomp base | Tren/Test 350 1 ml 2×/week (200 mg Tren E + 500 mg Test E/week) + Arimidex Dragon Pharma 0.5 mg EOD + Caberlin (Cabergoline) 0.25 mg 2×/week | The standalone blend at 1 ml 2×/week delivers a strong anabolic stimulus with manageable support requirements; Arimidex controls E2 from the Test E component (target 20–40 pg/mL); Caberlin prevents prolactin accumulation from Tren's progestogenic activity (target prolactin <25 ng/mL); this base protocol is appropriate for the first 4 weeks while side effect tolerability is being assessed before adding oral compounds; AI dose should be adjusted based on E2 bloodwork at week 3–4 rather than estimated |
| Lean mass + strength (oral add-on) | Tren/Test 350 1 ml 2×/week + Anavar 50 Dragon Pharma 40–60 mg/day (weeks 5–16) + Arimidex 0.5 mg EOD + Caberlin 0.25 mg 2×/week | Anavar (oxandrolone) adds strength and lean mass through AR activation without additional aromatization or liver stress at moderate doses; its mild DHT-derivative structure complements trenbolone's dry, hard muscle appearance; the combination produces excellent strength-to-weight improvements with minimal water retention, making it particularly effective for athletes with weight class considerations or users targeting maximum lean mass per cycle; liver values (ALT/AST) should be monitored monthly during oral use; Anavar at 40–60 mg/day is well within the hepatically tolerable range but still benefits from monitoring |
| Mass phase kickstart | Tren/Test 350 1 ml 2×/week + Dianabol 20 Dragon Pharma 30–40 mg/day (weeks 1–4) + Aromasin Dragon Pharma 12.5 mg EOD + Caberlin 0.25 mg 2×/week | Dianabol provides rapid mass and strength accumulation during the 4-week window before Trenbolone Enanthate reaches stable plasma levels (approximately weeks 3–4 for full effect); the kickstart fills the "lag time" of the enanthate ester; Aromasin is preferred over Arimidex here because Dianabol adds substantial aromatization load on top of Test E, and Aromasin's suicidal mechanism provides more aggressive E2 control without rebound; the Dianabol-added water weight from glycogen and mild E2 elevation will shed after week 4, leaving the harder, leaner trenbolone-driven mass; hepatic support with NAC or UDCA is recommended during oral use |
| Contest prep / hardening | Tren/Test 350 1 ml 2×/week + Winstrol Inject Dragon Pharma 50 mg EOD (weeks 9–16) + Aromasin 12.5 mg EOD + Caberlin 0.25 mg 2×/week | Injectable Winstrol (stanozolol) in the final weeks adds SHBG-binding suppression (increasing free testosterone and trenbolone), additional strength, and pronounced muscle hardness and vascularity without aromatization; unlike oral Winstrol, the injectable form bypasses the first-pass hepatic metabolism while delivering equivalent or superior stanozolol plasma levels, making it the preferred form when already running an 8–10 week base; joint discomfort from stanozolol's SHBG suppression is common — ensure E2 is maintained in the 20–30 pg/mL range (not crashed) to mitigate; this is a competitive-level stack appropriate for advanced users in final contest preparation phases |
| Advanced dry mass | Tren/Test 350 1 ml 2×/week + Masteron 200 Dragon Pharma 400 mg/week + Aromasin 12.5 mg EOD + Caberlin 0.25 mg 2×/week | Masteron 200 (drostanolone enanthate) adds a DHT-derivative anti-estrogenic overlay to the Tren/Test base; Masteron displaces E2 from SHBG, increases free androgen fractions, and provides a tissue-level anti-estrogenic effect that complements the AI management from Aromasin; the three-compound combination (Test E + Tren E + Masteron E) is a classic advanced bodybuilding stack for maximum dry lean mass with all three compounds sharing the Enanthate ester and identical injection scheduling; the matched esters allow all three to be loaded in the same syringe, further simplifying injection logistics; total weekly androgenic load is high — careful monitoring of hematocrit, blood pressure, and lipids is mandatory at this stack level |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| Estrogenic effects — E2 elevation from Test E aromatization | The Testosterone Enanthate component aromatises via CYP19A1 to oestradiol; at 500 mg/week Test E, E2 will typically reach 60–100+ pg/mL without AI management, producing water retention, bloating, gynecomastia progression, and elevated blood pressure; Trenbolone itself does not aromatise, so E2 load is proportional only to the Test E dose; blood pressure elevation from E2 excess occurs through sodium and water retention; gynecomastia risk is present if E2 exceeds 60–80 pg/mL without SERM coverage | Arimidex Dragon Pharma 0.5 mg EOD or Aromasin Dragon Pharma 12.5 mg EOD as the primary AI; Aromasin is preferred when adding orals that increase aromatization (Dianabol); target E2 20–40 pg/mL confirmed by bloodwork at week 3–4; do not estimate AI dose without labs — under-dosing allows E2 accumulation, over-dosing crashes E2 causing joint pain and libido loss; gynecomastia breakthrough: add Nolvadex Dragon Pharma 20–40 mg/day immediately |
| Prolactin elevation — 19-Nor progestogenic effect | Trenbolone's progesterone receptor activity stimulates prolactin release from the anterior pituitary; elevated prolactin causes nipple sensitivity, galactorrhoea (milky discharge), and sexual dysfunction; this is a distinct mechanism from estrogen-mediated gynecomastia and requires a different management approach — AIs do not address prolactin; prolactin elevation from Tren is dose-dependent and begins within 3–4 weeks of starting the cycle; at 200 mg/week Tren E (standard blend dose), prolactin typically reaches 25–40 ng/mL without cabergoline; target is <25 ng/mL throughout the cycle | Caberlin (Cabergoline) 0.25 mg twice weekly is the standard prolactin control protocol; start Caberlin week 1 of the cycle alongside AI; check prolactin at week 4 and adjust dose upward to 0.5 mg 2×/week if prolactin exceeds 30 ng/mL; do not wait for symptoms — prolactin-mediated gyno is more difficult to reverse than E2-mediated gyno once established; Caberlin is a dopamine agonist and lowers prolactin by suppressing anterior pituitary prolactin secretion |
| Blood pressure elevation and cardiovascular strain | Both Test E (via E2-driven water retention and sodium retention) and Trenbolone (via hematocrit elevation and viscosity increase) raise blood pressure; trenbolone independently increases left ventricular hypertrophy risk and reduces cardiovascular compliance with extended use; blood pressure above 140/90 mmHg is common without active management on Tren/Test cycles, particularly in users with pre-existing hypertension or high dietary sodium; the cardiovascular impact of trenbolone is dose-dependent and accumulates with cycle length; this is the primary long-term safety concern of trenbolone use | Monitor blood pressure weekly throughout; maintain resting BP below 130/85 mmHg as the on-cycle target; if BP exceeds 140/90 mmHg: Amlip (Amlodipine) 5 mg/day as first-line CCB; escalate to Sartel (Telmisartan) 40–80 mg/day if CCB alone is insufficient — telmisartan also provides renal protection relevant to long-term AAS use; reduce or eliminate dietary sodium; cardiovascular aerobic exercise (zone 2 cardio, 3–4×/week) provides additive BP management; if BP cannot be maintained below 140/90 with medication and lifestyle, reduce the Tren E dose or consider early cycle termination |
| Hematocrit and hemoglobin elevation | Both testosterone and trenbolone stimulate renal EPO production and directly promote erythropoiesis in bone marrow, raising red blood cell count, hemoglobin, and hematocrit; at 500 mg/week Test E + 200 mg/week Tren E, hematocrit typically rises to 48–54% within 8–12 weeks; hematocrit above 52% significantly increases blood viscosity and thrombotic risk (deep vein thrombosis, pulmonary embolism); the risk is further elevated by dehydration, which concentrates red blood cell mass | Test hematocrit at baseline, week 6, and end of cycle; if hematocrit exceeds 50%: add Ecosprin (Aspirin) 75 mg/day as antiplatelet therapy to reduce thrombotic risk; maintain adequate daily hydration (3–4 L water/day); if hematocrit exceeds 54%: donate blood (therapeutic phlebotomy) or consider cycle dose reduction; do not ignore elevated hematocrit — it is the most clinically underappreciated AAS cardiovascular risk factor |
| Night sweats and insomnia | Trenbolone-specific side effects caused by its thermogenic-like effect on basal metabolic rate and its direct stimulatory action on the central nervous system; many users experience profuse nocturnal sweating, difficulty falling asleep, and disrupted sleep architecture particularly in the first 4–8 weeks; severity is highly dose-dependent and individual; Tren E produces milder but longer-lasting CNS stimulation compared to Tren A (acetate) because of the more gradual plasma curve; night sweats are particularly disruptive at doses above 300 mg/week | Keep bedroom temperature low (16–19°C / 60–66°F) and use breathable bedding; avoid training within 3 hours of sleep; reduce alcohol and caffeine intake during the cycle; Meloset (Melatonin) 0.5–3 mg 30 minutes before sleep as a first-line intervention for sleep onset issues; if melatonin is insufficient: Hypnite (Eszopiclone) 1–2 mg; persistent severe sleep disruption despite management is a signal to reduce the Tren E dose, as sleep quality has significant downstream effects on recovery, training output, and cortisol levels |
| Lipid suppression (HDL reduction, LDL elevation) | Both testosterone and trenbolone suppress HDL cholesterol and raise LDL; trenbolone has a more adverse lipid impact per milligram than testosterone due to its lack of estrogenic activity (estrogen supports HDL) and its strong AR activity in the liver altering lipid metabolism; at 200 mg/week Tren E + 500 mg/week Test E, HDL suppression of 30–50% from baseline is typical without lipid support; the lipid impact is partly offset by the test component's estrogenic HDL benefit when E2 is in range, but the net lipid impact of this stack remains significantly adverse versus baseline | Lipid panel at baseline and week 8; if HDL falls below 35 mg/dL or LDL rises above 160 mg/dL: Atorvastatin 40 mg Dragon Pharma once daily or Rosulip (Rosuvastatin) 10 mg/day for more aggressive LDL reduction; omega-3 fatty acids 3–4 g/day provide modest HDL support; cardiovascular aerobic training is the most effective non-pharmacological intervention for HDL preservation during AAS cycles; lipid management should begin as soon as bloodwork confirms suppression, not after the cycle ends |
| Androgenic effects — acne, hair loss | Trenbolone does not convert to DHT via 5-alpha reductase (it produces weaker 5AR metabolites) but its own AR affinity in skin and hair follicles is sufficiently high to produce significant androgenic side effects; acne on the back, shoulders, and chest is common, particularly in users with prior androgenic sensitivity; hair loss acceleration follows the classic androgenic alopecia pathway and is dose-dependent; the Test E component adds DHT-pathway androgenic effects on top of the direct tren-AR effects, compounding acne and hair loss risk in genetically predisposed users | Acne: Accutane (Isotretinoin) Dragon Pharma 10–20 mg/day for moderate-to-severe acne; benzoyl peroxide body wash as a preventative measure; keep injection sites clean; hair loss: Finasteride Dragon Pharma 1 mg/day reduces DHT from the Test E component but does not block trenbolone's direct AR effects on scalp follicles — its benefit is partial on Tren cycles; users with advanced male pattern baldness should assess the risk-to-benefit ratio of this stack specifically before starting |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Hematocrit & Hemoglobin | Baseline; week 6; end of cycle | Hematocrit <50%; Hemoglobin <17.5 g/dL — if hematocrit >52%: add Ecosprin 75 mg/day and increase hydration; if >54%: therapeutic phlebotomy or dose reduction |
| CBC (full blood count) | Baseline; week 6 | WBC, platelet count within reference range; red cell distribution width (RDW) as an additional erythropoiesis marker; flag any significant deviation from pre-cycle baseline |
| Lipid Panel (total cholesterol, LDL, HDL, triglycerides) | Baseline; week 8 | HDL >40 mg/dL; LDL <130 mg/dL; total cholesterol <200 mg/dL — if HDL <30 or LDL >160: initiate Atorvastatin 40 mg or Rosulip 10 mg; re-test 4 weeks after initiating statin therapy |
| Estradiol (E2) | Week 3–4; week 8; adjust AI based on result | Target 20–40 pg/mL on-cycle — >50 pg/mL: increase AI dose; <15 pg/mL: reduce AI dose (crashed E2 causes joint pain, low libido, poor recovery); do not dose AI by symptom alone |
| Prolactin | Week 4; week 8 | Target <25 ng/mL — 25–35 ng/mL: maintain Caberlin 0.25 mg 2×/week; >35 ng/mL: increase Caberlin to 0.5 mg 2×/week; prolactin above 50 ng/mL with symptoms warrants Tren E dose reduction |
| Blood Pressure (systolic / diastolic) | Weekly throughout cycle — home cuff measurement | Target <130/85 mmHg — persistent >140/90: initiate Amlip 5 mg/day; if uncontrolled with CCB: add Sartel 40–80 mg/day; BP above 160/100 is a cycle-stop signal pending pharmacological control |
| LH & FSH | End of PCT only (4–6 weeks post-cycle) | Both should be recovering toward mid-normal range by PCT end; persistently suppressed LH/FSH at PCT week 4 indicates need for extended SERM protocol or HCG addition |
| Total Testosterone | 4–6 weeks after completing PCT | >400 ng/dL confirms adequate HPG axis recovery; 300–400 ng/dL with normalising LH/FSH: extend monitoring; <300 ng/dL at 6 weeks post-PCT with flat LH/FSH: specialist assessment warranted |
Post-Cycle Recovery
| Compound | Protocol | Notes |
|---|---|---|
| HCG 5000 IU Dragon Pharma | 500–1,000 IU EOD for 2 weeks during the ester clearance window (days 1–14 after last injection, before SERM start) | Trenbolone produces profound HPG axis suppression — more severe than testosterone-only cycles; HCG is strongly recommended (not optional) before the SERM phase to restore testicular volume and Leydig cell sensitivity; discontinue HCG before starting SERM as concurrent HCG raises intratesticular E2 and partially counteracts SERM-driven HPG stimulation; see full PCT protocol guide |
| Nolvadex Dragon Pharma | 40 mg/day weeks 1–2; 20 mg/day weeks 3–6. Start 2 weeks after last Tren/Test 350 injection | Primary SERM for HPG axis recovery; 6-week protocol is standard for cycles involving trenbolone due to the deeper suppression relative to testosterone-only cycles; E2 and total testosterone check at PCT week 4 confirms recovery trajectory |
| Clomid Dragon Pharma | 50 mg/day weeks 1–2; 25 mg/day weeks 3–4 (alongside Nolvadex for severe suppression cases) | Add Clomid when prior Nolvadex-only PCT produced incomplete recovery (LH/FSH remained suppressed at PCT end), or when cycle length exceeded 16 weeks or involved high-dose Tren; dual SERM stimulation drives more aggressive HPG axis recovery; run Clomid at lower doses alongside Nolvadex rather than at full Clomid-monotherapy doses |
| Enclomiphene Dragon Pharma | 25 mg/day × 6 weeks as an alternative to Clomid | Enclomiphene (the active trans-isomer of clomiphene) provides strong LH-stimulating SERM activity with fewer mood and visual side effects than full clomiphene; suitable for users who tolerate clomiphene poorly; produces equivalent or superior testosterone recovery to clomiphene monotherapy in clinical data |
Practical Summary
- Tren/Test 350 is an advanced-only compound — prior trenbolone acetate experience is the minimum requirement before running the enanthate blend; the 7–10 day ester half-life means any intolerable side effect takes 2–3 weeks to fully clear after discontinuation, removing the rapid exit strategy that acetate provides; do not use this blend as a first trenbolone experience
- Run Caberlin (cabergoline) from day one — prolactin elevation from trenbolone's progestogenic activity begins within week 2–3; starting cabergoline reactively after prolactin symptoms appear (nipple sensitivity, sexual dysfunction) is later than optimal; 0.25 mg twice weekly is the standard prophylactic dose; confirm prolactin at week 4 and adjust accordingly
- AI dose must be guided by bloodwork, not by symptom estimation — E2 bloodwork at week 3–4 is non-negotiable; the combination of Test E aromatization and trenbolone's water-free physique can mask E2 elevation (less visible water retention than test-only cycles), leading to underestimation of E2 levels and delayed AI adjustment; test, don't guess
- Blood pressure monitoring is mandatory weekly throughout — trenbolone's cardiovascular impact accumulates over the cycle duration; a blood pressure reading of 130/85 at week 4 that is ignored can become 150/95 by week 10; home cuff measurement is sufficient; keep Amlip on hand before starting the cycle, not as a reactive purchase
- Hematocrit above 50% requires Ecosprin 75 mg/day and increased hydration immediately — above 54%: donate blood or reduce dose; this is the single most underappreciated AAS safety metric and is directly actionable without medical intervention at the Ecosprin level
- PCT for Tren/Test 350 cycles is more demanding than test-only PCT: HCG bridge (2 weeks during ester clearance) followed by a 6-week SERM protocol is the standard; the deeper HPG suppression of trenbolone means a 4-week SERM protocol is often insufficient; do not shorten PCT based on feeling well — confirm recovery with LH, FSH, and testosterone bloodwork before discontinuing
Tren/Test 350 Dragon Pharma represents one of the most potent injectable blend configurations available at steroidwarehouse.com, delivering the dual pharmacological impact of trenbolone's unmatched nutrient partitioning and AR potency alongside testosterone enanthate's anabolic foundation and hormonal completeness in a single, twice-weekly injection. For experienced users who have assessed their trenbolone tolerance and established functional support protocols, the Enanthate ester blend removes the injection frequency burden of short-ester alternatives while delivering sustained anabolic stimulus across a 10–16 week cycle. The results — dry, dense lean mass accrual, exceptional strength progression, and body recomposition that is difficult to replicate with any other compound class — justify its position as the benchmark advanced bodybuilding stack, provided the side effect management discipline that trenbolone demands is applied consistently and verified with regular bloodwork throughout.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training; foundational evidence for supraphysiologic androgen anabolic effects | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, oral and injectable steroid classes, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, 5α-reduction, estradiol aromatization, synthetic androgen pharmacology, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| American Journal of Physiology-Endocrinology and Metabolism / PubMed | Bhasin et al. 2001 — graded testosterone enanthate dose-response study using 25–600 mg/week for 20 weeks under GnRH suppression; documents dose-dependent changes in fat-free mass, muscle size, strength, power, fat mass, hemoglobin, HDL cholesterol, and IGF-I | Bhasin S, et al. (2001) ↗ |
| Steroids / PubMed | Donner et al. 2015 — preclinical rat study showing that trenbolone improved body composition, cardiometabolic risk markers, and insulin sensitivity in normogonadic rats; useful as trenbolone-specific mechanistic context, but not direct human cardiovascular safety evidence | Donner DG, et al. (2015) ↗ |
| Circulation / PubMed | Baggish et al. 2017 — human study of cardiovascular toxicity associated with long-term illicit anabolic-androgenic steroid use; links chronic AAS exposure with myocardial dysfunction and accelerated coronary atherosclerosis | Baggish AL, et al. (2017) ↗ |
What is Tren/Test 350?
Tren/Test 350 is an injectable steroid blend for lean muscle; see What is Tren/Test 350. It's potent—consult professionals for safe use.
How much Tren/Test 350 for bodybuilding?
350-700 mg/week, split into 1-2 injections; see How Much Tren/Test 350 for Bodybuilding. Start at 350 mg—consult professionals for dosing.
How does Tren/Test 350 work?
It combines Trenbolone and Testosterone for muscle and fat loss; see Mechanism of Action. It delivers dramatic results—monitor with labs.
What is Tren/Test 350 used for?
It's used for lean muscle, strength, and fat loss in cutting or recomp; see Key Benefits. It suits advanced users—use with professional oversight.
What are the main benefits of Tren/Test 350?
Commonly reported benefits include increased lean muscle mass, enhanced strength, improved muscle hardness, accelerated recovery, and strong physique recomposition effects.
Is Tren/Test 350 better for bulking or cutting?
Tren/Test 350 is often associated with recomposition and cutting phases due to its reputation for producing a lean, hard, and defined physique while preserving muscle mass.
What are the possible side effects of Tren/Test 350?
Potential side effects may include insomnia, increased sweating, mood changes, elevated blood pressure, acne, and suppression of natural testosterone production.
What makes Tren/Test 350 different from single-compound products?
Tren/Test 350 combines two potent anabolic agents in one blend, offering both testosterone support and trenbolone-driven muscle density and hardness effects.